Skip To Main Content

Deze website is alleen bedoeld voor zorgverleners van België en Luxemburg.

Dyslipidemie

Opleiding

Understanding Cardiovascular Risk and Prevention: Insights from Professor Pasquale Perrone-Filardi

Understanding Cardiovascular Risk and Prevention: Insights from Professor Pasquale Perrone-Filardi

Preventive Cardiology: Key Insights from Professor Michal Vrablik

Preventive Cardiology: Key Insights from Professor Michal Vrablik

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

Roth Eli M et al. Atherosclerosis vol. 254 (2016): 254-262

Why Don’t We Strike Early, Strike Strong?

Why Don’t We Strike Early, Strike Strong?

Prof. Dr. Halvorsen, Prof. Dr. Sinnaeve & Prof. Dr. Martens

Europese richtlijnen in de behandeling van hypercholesterolemie

Europese richtlijnen in de behandeling van hypercholesterolemie

Europese richtlijnen in de behandeling van hypercholesterolemie

Europese richtlijnen in de behandeling van hypercholesterolemie

Werkzaamheid van statines en de kracht van combinatie

Werkzaamheid van statines en de kracht van combinatie

Odyssey Outcomes Education